Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (131-140 of 436) with videos related to

Pageof 44
Sort By:
Blood Advances|February 24, 2022
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapySangeetha Venugopal, Gautam Borthakur, Naval Daver, et al.
American Journal of Hematology|May 12, 2017
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaBrittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaKoji Sasaki, Elias Jabbour, Jorge Cortes, et al.
Leukemia & Lymphoma|July 23, 2020
Clonal evolution with acquisition of <i>BCR-ABL1</i> in refractory acute myeloid leukemia post therapy with FLT3-inhibitorBeenu Thakral, Naval Daver, Zhenya Tang, et al.
The Lancet. Haematology|October 6, 2015
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyPreetesh Jain, Hagop Kantarjian, Elias Jabbour, et al.
Cancer|April 17, 2018
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeRita Assi, Hagop M Kantarjian, Tapan M Kadia, et al.
American Journal of Hematology|August 27, 2025
Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based RegimensHannah Goulart, Elias Jabbour, Nicholas Short, et al.
The Lancet. Haematology|December 22, 2015
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsKoji Sasaki, Sara S Strom, Susan O'Brien, et al.
Haematologica|June 20, 2015
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosisNaval Daver, Jorge Cortes, Kate Newberry, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapyNaval Daver, Theresa Liu Dumlao, Farhad Ravandi, et al.
Pageof 44

Showing results (131-140 of 436) with videos related to

Sort By:
Pageof 44
Blood Advances|February 24, 2022
Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapySangeetha Venugopal, Gautam Borthakur, Naval Daver, et al.
American Journal of Hematology|May 12, 2017
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemiaBrittany Knick Ragon, Naval Daver, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2016
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of MyelodysplasiaKoji Sasaki, Elias Jabbour, Jorge Cortes, et al.
Leukemia & Lymphoma|July 23, 2020
Clonal evolution with acquisition of <i>BCR-ABL1</i> in refractory acute myeloid leukemia post therapy with FLT3-inhibitorBeenu Thakral, Naval Daver, Zhenya Tang, et al.
The Lancet. Haematology|October 6, 2015
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 studyPreetesh Jain, Hagop Kantarjian, Elias Jabbour, et al.
Cancer|April 17, 2018
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeRita Assi, Hagop M Kantarjian, Tapan M Kadia, et al.
American Journal of Hematology|August 27, 2025
Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based RegimensHannah Goulart, Elias Jabbour, Nicholas Short, et al.
The Lancet. Haematology|December 22, 2015
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsKoji Sasaki, Sara S Strom, Susan O'Brien, et al.
Haematologica|June 20, 2015
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosisNaval Daver, Jorge Cortes, Kate Newberry, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapyNaval Daver, Theresa Liu Dumlao, Farhad Ravandi, et al.
Pageof 44